Aberrant signaling in the TNFα/TNF receptor 1 pathway of the NZM2410 lupus-prone mouse

Clinical Immunology

Volumn 110, Issue 2, 2004, Pages 124-133

  Blenman, Kim R M ^a   Bahjat, Frances R ^a   Moldawer, Lyle L ^a   Morel, Laurence ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

(p55) TNF receptor 1; Apoptosis; AST; B6; C57BL 6J; Cytokine; Endotoxic shock; FADD; FAS associated death domain; Lupus; QTL; Quantitative trait loci; Recombinant human TNF ; RhTNF ; Rodent; SLE; Systemic lupus erythematosus; TNFR1

Indexed keywords

CASPASE 3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; ASPARTATE AMINOTRANSFERASE; CASP3 PROTEIN, MOUSE; CASPASE; GALACTOSAMINE; INTERLEUKIN 10; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR RECEPTOR;

ALLELE; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOWNSTREAM PROCESSING; FEMALE; GENE MAPPING; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BLOOD; C57BL MOUSE; CONGENIC STRAIN; CYTOTOXICITY TEST; IMMUNOLOGY; LIVER; METABOLISM; NICK END LABELING; PATHOLOGY;

ANIMALS; ANTIGENS, CD; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; CASPASE 3; CASPASES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GALACTOSAMINE; IN SITU NICK-END LABELING; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIVER; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, CONGENIC; MICE, INBRED C57BL; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1542270904     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2003.09.009     Document Type: Article

References (63)

1. Hayashi T., Faustman D.L. Implications of altered apoptosis in diabetes mellitus and autoimmune disease. Apoptosis. 6:2001;31-45.
2. Zhou T., Edwards C.K. III, Yang P., Wang Z., Bluethmann H., Mountz J.D. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J. Immunol. 156:1996;2661-2665.
3. Wilson A.G., Gordon C., di Giovine F.S., de Vries N., van de Putte L.B., Emery P., Duff G.W. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur. J. Immunol. 24:1994;191-195.
4. Fujimura T., Hirose S., Jiang Y., Kodera S., Ohmuro H., Zhang D., Hamano Y., Ishida H., Furukawa S., Shirai T. Dissection of the effects of tumor necrosis factor-alpha and class II gene polymorphisms within the MHC on murine systemic lupus erythematosus (SLE). Int. Immunol. 10:1998;1467-1472.
5. Theofilopoulos A.N., Lawson B.R. Tumour necrosis factor and other cytokines in murine lupus. Ann. Rheum. Dis. 58(Suppl 1):1999;I49-I55.
6. Rudofsky U.H., Evans B.D., Balaban S.L., Mottironi V.D., Gabrielsen A.E. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab. Invest. 68:1993;419-426.
7. Morel L., Rudofsky U.H., Longmate J.A., Schiffenbauer J., Wakeland E.K. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity. 1:1994;219-229.
8. Morel L., Wakeland E.K. Lessons from the NZM2410 model and related strains. Int. Rev. Immunol. 19:2000;423-446.
9. Wakeland E.K., Wandstrat A.E., Liu K., Morel L. Genetic dissection of systemic lupus erythematosus. Curr. Opin. Immunol. 11:1999;701-707.
10. Morel L., Yu Y., Blenman K.R., Caldwell R.A., Wakeland E.K. Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm. Genome. 7:1996;335-339.
11. Jacob C.O., McDevitt H.O. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature. 331:1988;356-358.
12. Jacob C.O., Lee S.K., Strassmann G. Mutational analysis of TNF-alpha gene reveals a regulatory role for the 3′-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J. Immunol. 156:1996;3043-3050.
13. Di Marco S., Hel Z., Lachance C., Furneaux H., Radzioch D. Polymorphism in the 3′-untranslated region of TNFalpha mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNFalpha mRNA. Nucleic Acids Res. 29:2001;863-871.
14. Jacob C.O., Tashman N.B. Disruption in the AU motif of the mouse TNF-alpha 3′ UTR correlates with reduced TNF production by macrophages in vitro. Nucleic Acids Res. 21:1993;2761-2766.
15. Mohan C., Alas E., Morel L., Yang P., Wakeland E.K. Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J. Clin. Invest. 101:1998;1362-1372.
16. Mohan C., Morel L., Yang P., Wakeland E.K. Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J. Immunol. 159:1997;454-465.
17. Mohan C., Yu Y., Morel L., Yang P., Wakeland E.K. Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J. Immunol. 162:1999;6492-6502.
18. Morel L., Croker B.P., Blenman K.R., Mohan C., Huang G., Gilkeson G., Wakeland E.K. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc. Natl. Acad. Sci. U. S.A. 97:2000;6670-6675.
19. Galanos C., Freudenberg M.A., Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. U. S. A. 76:1979;5939-5943.
20. Leist M., Gantner F., Bohlinger I., Tiegs G., Germann P.G., Wendel A. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am. J. Pathol. 146:1995;1220-1234.
21. Morikawa A., Sugiyama T., Kato Y., Koide N., Jiang G.Z., Takahashi K., Tamada Y., Yokochi T. Apoptotic cell death in the response of D-galactosamine-sensitized mice to lipopolysaccharide as an experimental endotoxic shock model. Infect. Immun. 64:1996;734-738.
22. Nowak M., Gaines G.C., Rosenberg J., Minter R., Bahjat F.R., Rectenwald J., MacKay S.L., Edwards C.K., Moldawer L.L. LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 278:2000;R1202-R1209.
23. Mignon A., Rouquet N., Fabre M., Martin S., Pages J.C., Dhainaut J.F., Kahn A., Briand P., Joulin V. LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. Am. J. Respir. Crit Care Med. 159:1999;1308-1315.
24. Leist M., Gantner F., Kunstle G., Bohlinger I., Tiegs G., Bluethmann H., Wendel A. The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure. Mol. Med. 2:1996;109-124.
25. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods. 95:1986;99-105.
26. Tiegs G., Wolter M., Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol. 38:1989;627-631.
27. Bahjat F.R., Dharnidharka V.R., Fukuzuka K., Morel L., Crawford J.M., Clare-Salzler M.J., Moldawer L.L. Reduced susceptibility of nonobese diabetic mice to TNF-alpha and D-galactosamine-mediated hepatocellular apoptosis and lethality. J. Immunol. 165:2000;6559-6567.
28. Cross J.T., Benton H.P. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm. Res. 48:1999;255-261.
29. Spronk P.E., ter Borg E.J., Limburg P.C., Kallenberg C.G. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin. Exp. Immunol. 90:1992;106-110.
30. Grondal G., Gunnarsson I., Ronnelid J., Rogberg S., Klareskog L., Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 18:2000;565-570.
31. Jensen L.E., Whitehead A.S. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem. J. 334(Pt 3):1998;489-503.
32. Barton B.E. IL-6: insights into novel biological activities. Clin. Immunol. Immunopathol. 85:1997;16-20.
33. Tilg H., Dinarello C.A., Mier J.W. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol. Today. 18:1997;428-432.
34. Opal S.M., De Palo V.A. Anti-inflammatory cytokines. Chest. 117:2000;1162-1172.
35. Bijl M., Horst G., Bijzet J., Bootsma H., Limburg P.C., Kallenberg C.G. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis Rheum. 48:2003;248-254.
36. Burlingame R.W., Volzer M.A., Harris J., Du Clos T.W. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J. Immunol. 156:1996;4783-4788.
37. Moore K.W., de Waal M.R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:2001;683-765.
38. Brouckaert P., Libert C., Everaerdt B., Fiers W. Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokine Cytokine Res. 11:1992;193-196.
39. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 364:1993;806-809.
40. Ashkenazi A., Dixit V.M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11:1999;255-260.
41. Morel L., Tian X.H., Croker B.P., Wakeland E.K. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity. 11:1999;131-139.
42. Morel L., Blenman K.R., Croker B.P., Wakeland E.K. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1787-1792.
43. Brennan D.C., Yui M.A., Wuthrich R.P., Kelley V.E. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J. Immunol. 143:1989;3470-3475.
44. Jacob C.O., Hwang F., Lewis G.D., Stall A.M. Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation. Cytokine. 3:1991;551-561.
45. Gordon C., Ranges G.E., Greenspan J.S., Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin. Immunol. Immunopathol. 52:1989;421-434.
46. Huppertz B., Frank H.G., Kaufmann P. The apoptosis cascade-morphological and immunohistochemical methods for its visualization. Anat. Embryol. (Berlin). 200:1999;1-18.
47. Tsao B.P., Cantor R.M., Grossman J.M., Shen N., Teophilov N.T., Wallace D.J., Arnett F.C., Hartung K., Goldstein R., Kalunian K.C., Hahn B.H., Rotter J.I. PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. J. Clin. Invest. 103:1999;1135-1140.
48. Criswell L.A., Moser K.L., Gaffney P.M., Inda S., Ortmann W.A., Lin D., Chen J.J., Li H., Gray-McGuire C., Neas B.R., Rich S.S., Harley J.B., Behrens T.W., Seldin M.F. PARP alleles and SLE: failure to confirm association with disease susceptibility. J. Clin. Invest. 105:2000;1501-1502.
49. Rothe J., Lesslauer W., Lotscher H., Lang Y., Koebel P., Kontgen F., Althage A., Zinkernagel R., Steinmetz M., Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 364:1993;798-802.
50. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M.E. Apoptosis signaling by death receptors. Eur. J. Biochem. 254:1998;439-459.
51. Taniguchi T., Kanakura H., Yamamoto K. Effects of posttreatment with propofol on mortality and cytokine responses to endotoxin-induced shock in rats. Crit. Care Med. 30:2002;904-907.
52. Cain W.C., Stuart R.W., Lefkowitz D.L., Starnes J.D., Margolin S., Lefkowitz S.S. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int. J. Immunopharmacol. 20:1998;685-695.
53. Blackwell T.S., Christman J.W. Sepsis and cytokines: current status. Br. J. Anaesth. 77:1996;110-117.
54. Meijer C., Huysen V., Smeenk R.T., Swaak A.J. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus. 2:1993;359-365.
55. Alleva D.G., Kaser S.B., Beller D.I. Aberrant cytokine expression and autocrine regulation characterize macrophages from young MRL+/+ and NZB/W F1 lupus-prone mice. J. Immunol. 159:1997;5610-5619.
56. Llorente L., Richaud-Patin Y., Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., Alcocer-Varela J., Grangeot-Keros L., Alarcon-Segovia D., Wijdenes J., Galanaud P., Emilie D. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43:2000;1790-1800.
57. Kalechman Y., Gafter U., Da J.P., Albeck M., Alarcon-Segovia D., Sredni B. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J. Immunol. 159:1997;2658-2667.
58. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179:1994;305-310.
59. Yin Z., Bahtiyar G., Zhang N., Liu L., Zhu P., Robert M.E., McNiff J., Madaio M.P., Craft J. IL-10 regulates murine lupus. J. Immunol. 169:2002;2148-2155.
60. Bijl M., Limburg P.C., Kallenberg C.G. New insights into the pathogenesis of systemic lupus erythematosus (SLE): the role of apoptosis. Neth. J. Med. 59:2001;66-75.
61. Bickerstaff M.C., Botto M., Hutchinson W.L., Herbert J., Tennent G.A., Bybee A., Mitchell D.A., Cook H.T., Butler P.J., Walport M.J., Pepys M.B. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5:1999;694-697.
62. Du Clos T.W., Zlock L.T., Hicks P.S., Mold C. Decreased autoantibody levels and enhanced survival of (NZB × NZW) F1 mice treated with C-reactive protein. Clin. Immunol. Immunopathol. 70:1994;22-27.
63. Bopst M., Haas C., Car B., Eugster H.P. The combined inactivation of tumor necrosis factor and interleukin-6 prevents induction of the major acute phase proteins by endotoxin. Eur. J. Immunol. 28:1998;4130-4137.